Biosimilars have received a lot of attention and “buzz” lately. And, as the FDA continues to hold meetings and put out docu- ments for comment as it decides just how to eventually approve and regulate these biopharm generics there is one question that needs to be addressed.
What if doctors won’t prescribe them?
I pose this question in light of a recent survey that asked U.S.
and European endocrinologists if they would feel comfortable pre-
scribing biosimilar analogue insulins. The survey found that these
doctors would need extensive efficacy data from multiple
Phase III trials, involving in excess of 1,000 patients to feel
comfortable enough to prescribe biosimilar insulin.
The survey also revealed that if endocrinologists had to choose
between multiple biosimilars of the same reference product, the
most influential factors on their prescribing decision would be any
non-significant differences in the safety and efficacy, as well as the
robustness and number of clinical trials.
Granted this is just one group of doctors and one type of treatment – but this does not bode well for the biosimilars industry. As
their goal is to produce biopharmaceuticals that are cheaper than
the brand-name product – the possible future need to conduct
numerous Phase III trials to convince doctors (and patients) that
biosimilars are just as safe and effective as the original drug will
most certainly eat into profit margins – that are probably already
The established generics industry has had this same problem
for years – and although many doctors are now prescribing generics – I still see reminders in my local pharmacy that generics are
just like brand-name pharmaceuticals – just less expensive.
So what should the biosimilar industry do? Educate, inform, remind and reach out to doctors and patients at every opportunity.
■ FROM THE EDITOR
Close But No Cigar
Have a comment or question about Pharmaceutical Processing?
My E-mail is: firstname.lastname@example.org
As the FDA tries to decide just how to even-
tually approve and regulate these biopharm
generics there is one question that needs to
be addressed …
■ Michael Auerbach, Editor in Chief
Phone: 973-920-7793; Fax: 973-607-5682
ASSOCIATE PUBLISHER BILL KOENEN
AL, CT, DC, FL, GA, IA, IL, IN 199 EAST BADGER ROAD, SUITE 201
KY, MA, MI, MO, NH, NJ, NV Madison, WI 52713
NY, OH, PA, SC, TN, VT, WI Tel: 973-920-7793
NE W BRUNSWICK, ONTARIO, Fax: 973-607-5682
QUEBEC, CANADA email@example.com
SALES DAVID OLESTON
AR, AZ, BC, CA, CO 199 EAST BADGER ROAD, SUITE 201
DE, ID, SK, LA, MD Madison, WI 52713
ME, MN, MS, MT Tel: 973-920-7706
NC, NE, OK, OR Fax: 973-607-5516
SD, TX, UT, VA, WA firstname.lastname@example.org
ADMINISTRATIVE ASSISTANT ALYSSA ADAIR
WHITE PAPERS & WEBCASTS 973-920-7789
REPRINTS JESSICA STREMMEL
SUBSCRIPTION CHANGES Omeda Customer Service
LIST RENTALS Infogroup Targeting Solutions
Senior Account Manager
Bart Piccirillo; 402-836-6283;
Senior Account Manager
Michael Costantino; 402-863-6266
EDITORIAL ADVISORY BOARD
Michael J. Beier,
Senior Vice President of Operations
TITAN PHARMACEUTICALS, INC.
Dr. James V. Blackwell, PhD, Consultant
BIOPROCESS TECHNOLOGY CONSULTANTS, INC.
Ronald C. Branning,
Vice President Global Quality
Robert F. Dream, Vice President
H.D.R. COMPANY LTD.
Johanna Carmel Egan,
VGP Project Management
Girish Malhotra, President
Allan F. Pfitzenmaier, President
VECTECH PHARMA CONSULTANTS INC.
Susan Polizzotto, Manager,
R&D QA GMP Compliance
US SANOFI PASTEUR
Carlos Villalobos, Sr. Dir. Global Engineering
Richard G. Whitfield, Senior Director
Patrick Wong, Director of Global Engineering
BRISTOL-MYERS SQUIBB (BMS)